Table 4.
Measure | NUC | RUC | PUD | F(2, 59) | eta2 | Post-hoc | |||
---|---|---|---|---|---|---|---|---|---|
M | SD | M | SD | M | SD | ||||
SLF_R | 0.458 | 0.020 | 0.456 | 0.027 | 0.436 | 0.024 | 4.86* | 0.15 | NUC, RUC > PUD |
SLF_L | 0.448 | 0.019 | 0.444 | 0.021 | 0.423 | 0.022 | 8.12** | 0.22 | NUC, RUC > PUD |
SCR_R | 0.450 | 0.025 | 0.447 | 0.019 | 0.429 | 0.025 | 4.46* | 0.14 | NUC > PUD |
SCR_L | 0.455 | 0.021 | 0.449 | 0.023 | 0.431 | 0.026 | 5.27* | 0.16 | NUC > PUD |
p<.05,
p<.01, FA, Fractional Anisotropy; NUC, Non-using controls; RUC, Recreational using controls; PUD, Poly drug use disordered patients; FLS, Fasciculus longitudinalis superior; CRS, Corona radiata superior; L, Left; R, Right.